Abstract A036: Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer

Le résumé fourni par la source

Abstract Background: Effective treatment of ovarian cancer is limited by late-stage detection and chemotherapy resistance. There is a clinical need for the discovery of novel molecular targets to enable the development of innovative theranostic approaches. We investigated the coagulation factor II receptor (F2R/PAR1) as a potential diagnostic/prognostic biomarker and therapeutic target for ovarian cancer treatment. Methods: Public RNA-sequence and DNA microarray data were used to analyze F2R gene expression in ovarian cancers, with protein expression confirmed in tumor samples by flow cytometry, immunofluorescence and immunohistochemistry (IHC). Functional assays were conducted to study effects of F2R suppression on tumor progression. Results: Our analysis confirmed elevated F2R mRNA and protein expression in ovarian cancers, notably in patients with metastatic and chemotherapy resistant disease. Kaplan-Meier survival analysis demonstrated an association between high F2R protein detection and reduced progression-free survival. F2R suppression in ovarian cancer cell lines reduced tumor cell motility, invasion, spheroid formation, metabolism and enhanced carboplatin sensitivity. Conclusions: F2R is a compelling diagnostic/prognostic and therapeutic target, which could be used to treat chemotherapy resistant and metastatic disease. The evaluation of novel F2R targeting strategies, using antibody conjugated drugs or F2R ligand decorated drug carriers, could lead to the development of effective therapeutics for patients with ovarian cancer. Citation Format: Riya Khetan, Noor A. Lokman, Preethi Eldi, Zoe K. Price, Martin K. Oehler, Doug A. Brooks, Anton Blencowe, Sanjay Garg, Carmela Ricciardelli, Hugo Albrecht. Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr A036.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.